|
T22009 |
CB2 receptor agonist 2
|
ZINC72105556,4-Quinolone-3-Carboxamide Furan CB2 Agonist |
Cannabinoid Receptor
|
|
CB2 receptor agonist 2 (ZINC72105556) is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor, Ki = 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2. |
|
T10696 |
CB2 modulator 1
|
|
Cannabinoid Receptor
|
|
CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia. |
|
T24097 |
CB2 receptor agonist 3
|
GP-2A,GP 2A,GP2A |
|
|
GP 2A is a selective agonist of CB2 receptor. |
|
T82771 |
CB2-H
|
|
|
|
CB2-H is a dual-channel fluorescent probe designed for the concurrent detection of HOCl and ONOO- with two separate channels that avoid spectral cross-interference. It facilitates dual-channel fluorescence imaging to mon... |
|
T62631 |
CB2 receptor antagonist 1
|
|
|
|
Hexyl resorcinol derivative 29 is a CB2 selective competitive antagonist/reverse agonist demonstrating notable potency. Meanwhile, Olivanol and 5-(2-methyloctane-2-yl) resorcinol derivatives 23 and 24 exhibit substantial... |
|
T82772 |
CB2 receptor antagonist 2
|
|
|
|
Compound 39, also known as CB2 receptor antagonist 2, is a potent CB2 antagonist exhibiting an IC50 of 0.33 μM. It engages in strong interactions with residues L17, W6.48, V6.51, and C7.42 [1]. |
|
T79577 |
CB2 PET Radioligand 1
|
|
Cannabinoid Receptor
|
|
CB2 PET Radioligand 1 (compound [18F]9) is a positron emission tomography (PET) radioligand with high affinity for the human cannabinoid receptor 2 (hCB2, Ki=7.7 nM). It is synthesized via Cu-mediated 18F-fluorination an... |
|
T9687 |
MAGL-IN-4
|
His121 ARG57 |
Lipase
|
|
MAGL-IN-4 (His121 ARG57) is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases. |
|
T12306 |
OMDM-5
|
|
Cannabinoid Receptor
,
Endogenous Metabolite
,
TRP/TRPV Channel
|
|
OMDM-5 is a selective anandamide cellular uptake (ACU)inhibitor(Ki of 4.8 μM). |
|
T12302 |
OMDM-1
|
(Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide |
Endogenous Metabolite
|
|
OMDM-1 ((Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide) is a selective and metabolically stable anandamide cellular uptake (ACU)inhibitor with a Ki of 2.4 μM. |
|
T37075 |
CB2R PAM
|
Ec2la |
Cannabinoid Receptor
|
|
CB2R PAM is an orally active cannabinoid type 2 receptor (CB2Rs) positive mutational modulator that enhances CP 55940 and 2-Arachidonylglycerol-stimulated [35S]GTPγS binding to CB2 receptors, but has no effect in the abs... |
|
T67896 |
CB2R/FAAH modulator-1
|
|
Cannabinoid Receptor
,
FAAH
|
|
CB2R/FAAH modulator-1, a cannabinoid type 2 receptor (CB2R) agonist, is also a fatty acid amide hydrolase (FAAH) inhibitor (IC50=4 μM) that reduces the production of pro-inflammatory and anti-inflammatory cytokines and i... |
|
T25209 |
CB29
|
CB-29,CB 29 |
Dehydrogenase
|
|
CB29 is a specific inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1). |
|
T67747 |
CB2R/FAAH modulator-3
|
|
Cannabinoid Receptor
,
FAAH
|
|
CB2R/FAAH modulator-3 (compound 27) is a modulator targeting at CB2R and FAAH. CB2R/FAAH modulator-3 acts as a CB2R agonist and FAAH inhibitor, the Ki values are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the ... |
|
T8839 |
ICCB280
|
|
Apoptosis
,
Others
|
|
ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavo... |
|
T67745 |
CB2R/FAAH modulator-2
|
|
Cannabinoid Receptor
,
FAAH
|
|
CB2R/FAAH modulator-2 (compound 26) is a dual modulator targeting at CB2R and FAAH. CB2R/FAAH modulator-2 acts as a CB2R agonist and FAAH inhibitor, the Ki values are 10.8 and 152.9 nM for CB2R and CB1R, respectively, an... |
|
T10697 |
CB2R-IN-1
|
|
Others
|
|
CB2R-IN-1 is a potent inverse agonist of the cannabinoid CB2 receptor (Ki: 0.9 nM). |
|
T82770 |
CB2R agonist 2
|
|
Cannabinoid Receptor
|
|
CB2R agonist 2 (cis-17-para) is a CB2R agonist [1]. |
|
T82769 |
CB2R agonist 3
|
|
Cannabinoid Receptor
|
|
CB2R agonist 3, a potent activator of cannabinoid receptor 2 (CB2R), exhibits an EC50 value of 0.37μM, indicative of its significant role in the immune system [1]. |
|
T38757 |
KH-CB20
|
KH-CB20 |
|
|
KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and CLK4 , with an IC 50 of 16.5 nM for CLK1 . KH-CB20 also can inhibits DYRK1A ( IC 50 =57.8 nM) and CLK3 ( IC 50 =488 nM). |
|
T74604 |
CB2R probe 1
|
|
|
|
CB2R Probe 1, a cannabinoid 2 receptor (CB2R) fluorescent probe, exhibits both safety and environmental friendliness, boasting a dissociation constant (K i) of 130 nM. Notably, it demonstrates low cytotoxicity within can... |
|
T73326 |
CB2R-IN-3
|
|
|
|
CB2R-IN-3 is a selective antagonist of cannabinoid type 2 receptor (CB2R) . CB2R-IN-3 has high affinity for human CB2R and specific selectivity for CB1R. CB2R-IN-3 can be combined with CB65 , the activator of CB2R. CB2R-... |
|
T72849 |
CB2R agonist 1
|
|
|
|
CB2R agonist 1, a selective ligand for the cannabinoid receptor subtype 2 (CB2R), demonstrates a high affinity and excellent selectivity, with an EC50 value of 0.56 µM, favoring human CB2R over CB1R. It plays an immunomo... |
|
T41230 |
CB 65
|
|
Cannabinoid Receptor
|
|
CB 65 is a high affinity and selective CB2 receptor agonist with Ki values of 3.3 and > 1000 nM for CB2 and CB1 receptors respectively. |
|
T6417 |
BML-190
|
Indomethacin morpholinylamide,IMMA,BML 190 |
Cannabinoid Receptor
|
|
BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor. |
|
T16928 |
SR144528
|
|
Cannabinoid Receptor
|
|
SR144528 is an antagonist of the CB2 receptor (Ki = 0.6 nM) and inhibits microsomal ACAT activity (IC50 = 3.6 μM). |
|
T24771 |
SCH-336
|
SCH336,SCH 336 |
Cannabinoid Receptor
|
|
SCH-336 is a CB2 receptor agonist (Ki-1.8 nM, EC50-2 nM) with effective, selective, and oral activity. SCH-336 is also bioactive against CB1 receptor, and is 100 times more selective to CB2 receptor than CB1. SCH-336 red... |
|
T6755 |
AM1241
|
|
Cannabinoid Receptor
|
|
AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor. |
|
T7316 |
LY2828360
|
|
Cannabinoid Receptor
|
|
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). |
|
T14204 |
6-Iodopravadoline
|
AM630 |
Cannabinoid Receptor
|
|
6-Iodopravadoline (AM630) is an antagonist of CB2 (Ki: 31.2 nM). And it shows 165-fold selectivity more than CB1 receptors. |
|
T14302 |
Olorinab
|
APD 371 |
Cannabinoid Receptor
|
|
Olorinab (APD 371) (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2. |
|
T3699 |
Bay 59-3074
|
|
Cannabinoid Receptor
|
|
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties. |
|
T6527 |
GW842166X
|
|
Cannabinoid Receptor
|
|
GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2. |
|
T10694 |
CB1 inverse agonist 1
|
MRL-650 |
Cannabinoid Receptor
|
|
CB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively. CB1 inverse agonist 1 shows anorexigenic effects. |
|
TP1939L1 |
RVD-Hpα acetate(1193362-76-3 free base)
|
|
Cannabinoid Receptor
|
|
RVD-Hpα acetate is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. Increases intracellular Ca2+ levels in cells expressing CB1 receptors in vitro. Also high affinity CB2... |
|
T19705 |
JTE-907
|
JTE 907 |
Cannabinoid Receptor
|
|
JTE-907 is a CB2 receptor inverse agonist with high selectivity and oral activity.JTE-907 exhibits anti-inflammatory activity in vivo. |
|
T41231 |
GP 1a
|
|
Cannabinoid Receptor
,
PERK
,
Arrestin
|
|
GP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays. GP 1a is approximately 30-fold more selective for CB2 receptors than CB1 receptors and incr... |
|
T7375 |
A-836339
|
|
Cannabinoid Receptor
|
|
A-836339 acts as a potent cannabinoid receptor full agonist which has a higher affinity for the peripheral CB2 receptor (Ki = 0.64 nM) over the central CB1 receptor (Ki = 270 nM). It displays analgesic, anti-inflammatory... |
|
T2264 |
AM281
|
|
Cannabinoid Receptor
|
|
AM 281, a cannabinoid antagonist, reduces neurologic dysfunction and mortality rate after cecal ligation and puncture in rats. |
|
T64394 |
GW 833972A
|
|
Cannabinoid Receptor
|
|
GW 833972A is a selective CB2 receptor agonist.GW 833972A has an inhibitory effect on induced neural depolarization and on citric acid-induced cough in an animal model. |
|
T13289 |
EHP-101
|
VCE-004.8 |
Cannabinoid Receptor
,
HIF/HIF Prolyl-Hydroxylase
,
PPAR
|
|
EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. |
|
T22103 |
ML-193
|
CID 1261822 |
Cannabinoid Receptor
|
|
ML-193 (CID 1261822) is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkin... |
|
T1915 |
AM251
|
|
Cannabinoid Receptor
,
GPR
|
|
AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 nM). |
|
TP1901L1 |
Hemopressin (rat) acetate(568588-77-2 free base)
|
|
Cannabinoid Receptor
|
|
Hemopressin (rat) acetate is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB2 cannabinoid recept... |
|
T3530 |
Otenabant
|
CP-945598 |
Cannabinoid Receptor
|
|
Otenabant (CP-945598) has been investigated for the treatment of Obesity. |
|
T8571 |
ML-184
|
CID2440433 |
Cannabinoid Receptor
|
|
ML-184 (CID2440433) is a potent synthetic agonist of GPR55 with EC50 of 0.26 μM. |
|
T8425 |
Linoleoyl Ethanolamide
|
|
TRP/TRPV Channel
|
|
Linoleoyl Ethanolamide is an endocannabinoid agent. It acts by binding to TRPV1 increasing ERK phosphorylation and AP-1 dependent transcription in CB-receptor in an independent manner. |
|
T14504 |
BAY 38-7271
|
|
Cannabinoid Receptor
|
|
BAY 38-7271 has strong neuroprotective properties.[1] BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist. With Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 recept... |
|
T1519L |
Rimonabant
|
SR141716 |
Cannabinoid Receptor
,
Antibacterial
,
Acyltransferase
|
|
Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant... |
|
T5996 |
CB1-IN-1
|
DBPR211 |
Cannabinoid Receptor
|
|
CB1-IN-1 (DBPR211) is a peripherally restricted CB1R antagonist, for CB1R and CB2R with Ki of 0.3 nM and 21 nM,respectively. |
